FDA Rare Disease Evidence Principles (RDEP)

The Rare Disease Evidence Principles (RDEP) is a framework the FDA announced on September 3, 2025 to clarify how the agency will apply flexible evidentiary standards when reviewing new drugs for ultra-rare genetic diseases. It was developed jointly by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), and it addresses a problem sponsors in this space have raised for years: the traditional two-adequate-and-well-controlled-trial model that underlies FDA’s “substantial evidence of effectiveness” standard is often simply not achievable when a disease affects a few hundred people worldwide. RDEP does not create a new statutory pathway or designation category alongside Orphan Drug Designation — it is a policy statement about how FDA will exercise the flexibility it already has under existing law when a sponsor’s development program meets specific eligibility criteria.

Why RDEP exists: the small-population evidence problem

For most drugs, FDA’s substantial-evidence standard has historically been met with two independent adequate and well-controlled trials, though the agency has recognized since the 1997 FDA Modernization Act that a single trial plus confirmatory evidence can suffice in some circumstances. In ultra-rare disease programs, running even one traditional randomized controlled trial (RCT) can be impractical: there may not be enough diagnosed patients to power a study, randomizing a fraction of an already tiny population to placebo raises acute ethical concerns when a disease is rapidly progressive or fatal, and geographic dispersion of patients makes site-based recruitment slow and expensive. Sponsors in this position have long used single-patient and small-N trial designs, external and synthetic control arms, and natural history data on an ad hoc basis, without a consistent statement from FDA on how much weight the agency would give that evidence at review time. RDEP is FDA’s attempt to make that calculus predictable up front, before a sponsor commits years and capital to a pivotal study design.

Who qualifies: RDEP eligibility criteria

RDEP is narrowly scoped. According to FDA’s announcement, a candidate program must target a condition that:

Affects fewer than 1,000 people in the United States;
Results from a known, identifiable genetic defect;
Causes progressive functional deterioration leading to significant disability or death, typically within a short timeframe; and
Currently lacks adequate alternative therapies that alter the disease’s underlying trajectory.

That combination — ultra-rare, genetically defined, severely progressive, and underserved — is deliberately tight. Industry analysts have noted that the 1,000-patient threshold excludes the large majority of programs FDA designates as orphan drugs generally (Orphan Drug Designation itself uses a much broader U.S. prevalence threshold of fewer than 200,000 affected individuals — see Orphan Drug Designation: FDA Criteria, Process, and Incentives). RDEP is best understood as a sub-category within the broader rare-disease and orphan-drug landscape, not a replacement for it: a sponsor can hold Orphan Drug Designation, pursue a Rare Pediatric Disease Priority Review Voucher, and separately request RDEP treatment for how its evidence package will be evaluated, since these operate on different axes (tax/exclusivity incentives, review-timeline incentives, and evidentiary-standard flexibility, respectively).

The evidentiary principles RDEP establishes

The core of RDEP is a statement that FDA “expects that substantial evidence of effectiveness may generally be established based on one adequate and well-controlled study” for a qualifying program, provided that study is supported by robust confirmatory evidence. FDA has identified several categories of evidence it will consider as confirmatory:

Single-arm trial data. RDEP explicitly accepts single-arm trials — where every enrolled patient receives the investigational treatment and there is no concurrent randomized control group — as the pivotal study design, rather than treating them as inherently insufficient.
Natural history studies. Well-characterized data on how a disease progresses in untreated or standard-of-care patients, used as an external comparator against which treated-patient outcomes are judged.
Strong mechanistic and biomarker data. Evidence that a therapy engages its intended molecular target and produces a measurable, biologically plausible downstream effect, including biomarker-based endpoints tied to the underlying genetic defect.
Non-clinical model data. Findings from animal or cellular models of the disease that support a plausible mechanism of benefit.
Clinical pharmacodynamic findings. Human dose-response or target-engagement data collected outside the pivotal trial itself.
Case reports and expanded access data. Outcomes observed in patients treated outside a formal trial, including through compassionate use and expanded access programs.

Taken together, this is a totality-of-evidence approach: rather than requiring a second independent trial to confirm the first, FDA will weigh converging evidence from mechanistic, non-clinical, real-world, and natural-history sources against the single pivotal study’s results. The strength of that confirmatory package — not just its existence — determines whether it can substitute for a second controlled trial.

How the RDEP request process works

RDEP is not automatic; a sponsor requests it. Based on FDA’s public description of the process:

Sponsors must request RDEP treatment before initiating their pivotal study — this is a front-loaded, design-stage conversation, not something applied retroactively to a completed trial.
Applications are reviewed jointly by CDER and CBER teams, informed by FDA’s Rare Disease Policy and Portfolio Council.
The process is intended to include study-design discussions between the sponsor and FDA, and, where appropriate, patient listening sessions to incorporate patient and caregiver perspective on disease burden and acceptable trial design.

Because the eligibility criteria and the front-loaded request timing both point toward early engagement, sponsors developing an ultra-rare genetic disease therapy should raise RDEP eligibility in an early Type B or Type C meeting with the review division, alongside — not instead of — normal orphan drug and expedited-program planning (see Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review, and Breakthrough Therapy Designation, both of which a rare-disease program may pursue in parallel).

What RDEP is not

Two clarifications matter for accurate scoping:

RDEP is not a lowering of the approval standard. FDA has framed it as an application of existing statutory flexibility (the “substantial evidence” standard already permits reliance on a single trial with confirmatory evidence for any drug, not just rare-disease drugs) to a population where the alternative — requiring a second RCT — is frequently not achievable. The agency has been explicit that it still expects a rigorous confirmatory evidence package, not a waiver of evidence requirements.
RDEP is not the same instrument as Orphan Drug Designation or a Priority Review Voucher. Orphan Drug Designation confers tax credits, a user-fee waiver, and 7-year market exclusivity based on a broader prevalence threshold; PRV programs reward specific designation approvals with a transferable faster-review voucher usable on a future application. RDEP instead governs how the strength of a single pivotal study plus supporting evidence will be judged at the substantial-evidence stage. A program can be eligible for one, some, or all three, since they answer different regulatory questions.

A related, broader development: the “plausible mechanism” framework

In February 2026, FDA Commissioner Marty Makary and CBER Director Vinay Prasad published commentary describing a “plausible mechanism” framework and signaling that FDA’s default posture — for individualized genetic, cellular, and molecular therapies more broadly, not only the narrow RDEP-eligible ultra-rare category — is shifting toward one adequate and well-controlled study plus confirmatory evidence as the baseline expectation, rather than the exception. FDA followed with draft guidance on February 23, 2026 elaborating five elements of that framework: a defined genetic/molecular abnormality with a clear disease link, a therapy targeting that specific abnormality, reliance on well-characterized natural history data, confirmation the intended target was actually engaged, and demonstrated clinical improvement. Sponsors should treat this as a related but distinct, still-evolving policy track — the February 2026 draft guidance was open for public comment through April 27, 2026 — rather than assume it has formally superseded or been merged into the September 2025 RDEP announcement; verify current guidance status directly on FDA.gov before relying on either for a specific submission.

Practical implications for sponsors

Build the natural history dataset early. Because natural history data functions as an external comparator under RDEP, its quality and completeness directly determines how persuasive a single-arm pivotal trial will look at review. Starting a prospective or well-sourced retrospective natural history study years before the pivotal trial begins is now a strategic prerequisite, not a nice-to-have.
Invest in mechanistic and biomarker evidence in parallel with clinical development. Non-clinical model data, target-engagement pharmacodynamics, and biomarker-based endpoints are explicitly named confirmatory categories — treat them as core deliverables of the program, not supplementary appendices to the clinical study report.
Engage FDA before finalizing pivotal trial design. Because RDEP requests must precede initiation of the pivotal study, waiting until topline data are in hand forecloses the option. Raise RDEP eligibility explicitly in early-phase meetings with the review division.
Don’t assume eligibility. The under-1,000-patient, known-genetic-defect, rapidly-progressive-disease criteria are narrow by design. Programs for somewhat larger rare populations, non-genetic rare diseases, or slower-progressing conditions should plan around standard orphan-drug and expedited-program pathways rather than RDEP specifically — though it is worth watching whether the broader “plausible mechanism” framework extends comparable flexibility further.
Keep designations and pathways distinct in program planning. Track Orphan Drug Designation, expedited-program designations, and RDEP eligibility as separate workstreams with separate criteria and separate FDA touchpoints, even though a single ultra-rare program will often pursue several simultaneously.

Frequently asked questions

Is RDEP a formal FDA designation, like Orphan Drug Designation or Breakthrough Therapy Designation?

No. RDEP is a review-policy framework describing how FDA will evaluate evidence for qualifying programs, not a designation with its own statutory incentives (exclusivity, fee waivers, voucher eligibility). Sponsors request RDEP treatment for their evidentiary approach; they separately apply for designations like Orphan Drug Designation if seeking those incentives.

Does RDEP mean FDA will approve rare-disease drugs with less clinical evidence than before?

FDA has framed RDEP as clarifying how existing flexibility in the substantial-evidence standard applies to ultra-rare genetic disease programs, not as reducing the evidentiary bar. A single pivotal trial under RDEP must still be paired with a robust confirmatory evidence package spanning mechanistic, non-clinical, and/or natural history sources.

Can a gene therapy program use RDEP?

Gene and cell therapies reviewed by CBER are within scope if the underlying condition meets RDEP’s eligibility criteria (ultra-rare, genetically defined, progressive, underserved) — RDEP was developed jointly by CDER and CBER for exactly this reason. See also FDA Approval for Gene Therapy: The BLA, CBER, and RMAT Pathway Explained for the broader gene-therapy regulatory pathway.

What’s the difference between RDEP’s single-arm trial acceptance and a standard external-control or synthetic-control-arm approach?

They are closely related tools rather than distinct mechanisms — a single-arm RDEP trial commonly relies on natural history data as its external comparator, which is the same underlying logic used in synthetic and external control arm designs generally. See Digital Twins in Clinical Trials: Synthetic Control Arms and FDA’s Evolving Posture for more on how FDA evaluates external comparator evidence.

This guide reflects FDA’s public announcement of RDEP (September 3, 2025) and subsequent public commentary and draft guidance through mid-2026. Because FDA policy in this area is actively evolving — including the related February 2026 “plausible mechanism” draft guidance — sponsors should verify current requirements directly against FDA.gov before relying on this page for a specific regulatory submission.